logo
Making The Most Of Life With Chronic Migraine

Making The Most Of Life With Chronic Migraine

Yahoo10-07-2025
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."
Chronic migraine is a debilitating condition that's both painful and frustrating. It's defined as 15 or more headache days per month for more than three months, with at least eight of those days including migraine-specific symptoms: Nausea and vomiting. Mood changes. Sensitivity to light, sounds, and smells.
There's a decent chance you nodded your head to at least a couple of those symptoms. According to the American Migraine Foundation, 85 percent of the 4 million Americans who live with chronic migraine are women—possibly due to hormone fluctuations around menstruation, pregnancy, perimenopause, and menopause, among other triggers.
There's good news, though. Many women with chronic migraine have found ways to not only live with the condition, but thrive in spite of it. Women's Health spoke to three of them about their migraine journeys, from their first experiences with severe headaches to the management strategies that have allowed them to live their lives to the fullest.
Gina Romero, 33, a licensed therapist and group-practice owner in Las Vegas: 'I remember this so vividly. I was 23 years old, and I was driving home from work on a Friday night. I remember being annoyed because I thought that everyone was driving with their bright lights on, and I even flashed my brights at one driver—which I feel bad about, because they didn't do anything wrong! I got home after the 20-minute drive and my head hurt so badly. I ended up spending the next 24 hours in bed, battling a sharp pain that left me unable to function. After consulting with Dr. Google, I came to the conclusion that I had just had my first migraine. I assumed it was a fluke at the time, but it ended up being just the first of many over the next decade.'
Laura Haver, 46, an author, speaker, and coach in Chicago: 'I got my first migraine shortly after the birth of my first son. He was born in an emergency C-section. I had a lot of medical complications post-delivery. I never had headaches growing up, so when I got my first migraine, I was like, Whoa! What is this madness? My migraines began with fuzzy vision and/or neck, jaw, or shoulder pain. My symptoms would blow up to the point where I had to surrender to my 'cave'—my bedroom—with every single shade and curtain pulled and the door closed. I'd lie in pain for days at a time, barely eating until the migraine finally subsided.'
Angela Zade, 46, a marketing director in Phoenix: 'I'd been suffering with severe chronic migraines most of my adult life, but I hadn't realized they were migraines until I was formally diagnosed in 2018. I was often treated for sinus infections that were actually migraines. Migraine presents itself differently in every patient—it's like a moving target.'
Haver: 'My migraines had a large impact for too many years. I hated that my husband had to do everything while I was down with one, and I missed time with my kids. I was apprehensive about making plans to do anything, as I didn't want to have to cancel. I went to different doctors, neurologists, naturopaths, chiropractors, and more. I tried various medications, but they all seemed to have a boomerang effect, making my migraines worse. My naturopath thought my trigger was food-related, so I cut out processed and aged foods. I felt like I could barely eat anything. I was miserable. But I was still determined to do anything I could to stop my migraines.'
Zade: 'I was unable to work full-time, so I moved in with my parents at the obscene age of 39. 'Being normal' was out of the question for me, and I became incredibly isolated. Ultimately, I was hospitalized in October 2018 for 16 days, and again in November 2018 for five days at a clinic that used zero opiates. Instead, I was treated with non-opiate abortive medications that finally broke my ongoing migraine. The formula that worked for me included neuromodulating injectables every three months, as well as a tiered medication system that includes 'cycle breakers'—a cycle happens when migraines erupt from triggers like menstruation, wind, or sleep deprivation.'
Romero: 'Migraines have been a part of my life for over 10 years. At their worst, they've disrupted work, my social life, and relationships. My most severe migraine happened when I was 25; it left me with blurry vision and without feeling in my hands. My supervisor had to drive me home from work because it wasn't safe for me to be there—I worked in a prison at the time. I've canceled plans last-minute and worked through pain and discomfort, because the world doesn't stop for chronic illness. The unpredictability can feel isolating, especially when others don't understand that it's not 'just a headache.''
Romero: 'Managing migraines goes beyond just medication for me. I pay attention to early signs, like neck stiffness or sensory sensitivity, and try to act quickly. I focus on hydration, gentle movements, and managing my stress load. I've learned the hard way that pushing through only makes things worse, so now I plan recovery time into my schedule as a non-negotiable. Even if I can't prevent every migraine, these choices help reduce the intensity and impact.'
Zade: 'During my hospitalizations, other patients talked me into believing that I'd be in and out of the hospital for the rest of my life like them. A thoughtful psychologist on staff countered: 'The patients who got better are not here at this hospital to tell you that you, too, will get better.' And she was right. I haven't been hospitalized since. Thanks to my treatment plan, I'm back working full-time again, I rarely have to skip a social gathering, and I was able to have a migraine-free wedding day!'
Haver: 'I eat relatively healthy foods, and I make movement part of my routine, even just a simple walk. I drink enough water and get enough sleep. And if I begin to feel overly tired or worn out, I go to bed earlier, sneak in a nap, or do a short meditation to get back on track.'
Romero: 'I've tried a lot of things over the years, including medication, acupuncture, therapy, and stress management. I've learned to take a proactive, holistic approach. I track triggers and try not to override my body's early-warning signs. I also lean on routines that support my nervous system, such as consistent sleep and pacing my workload. These approaches aren't always perfect, but they help lower the frequency and severity of attacks. What's been most effective for me are sumatriptan injections. They work very quickly and reliably, and they've been the least disruptive to my daily life. When I take an injection, I'm typically able to return to normal life within 15 to 30 minutes. This is a huge win, as it sometimes took me 8 to 10 hours to recover with other medications.'
Haver: 'For years, once a migraine began, there was nothing I could do but wait it out in my cave. They even got so bad that I would throw up—until finally I took matters into my own hands and sought alternative solutions. A coach introduced me to the healing power of energy work. It was a game changer! I created my own daily energy practice—a fusion of energy clearing, meditation, mindfulness, prayer, and more. It helps me release stress. My migraines have since turned into occasional headaches.'
Zade: 'I still undergo neuromodulating treatments every three months. I continue care with my neurologist in Chicago, where I lived previously, and have also established care with a local neurologist here in Phoenix. It sounds extreme to have two neurologists, but when you were as debilitated as I was, you can't afford to take any chances. And I know that this journey is ongoing, especially as I enter perimenopause, with more hormonal changes that will undoubtedly impact my migraine-treatment plan.'
Haver: 'First thing: I'm sorry you're having a hard time. And like me, I bet you've been doing so much to try to stop getting migraines. In my experience, my migraines were my body's way of shutting down. I simply couldn't push through anymore. Once I began listening to my body, and honoring myself and my needs, I was able to slowly and significantly reduce my migraines. And if I can do it, you can do it too!'
Romero: 'You can build a full life, even with chronic migraines. It just might look different than you expected. Don't be afraid to rewrite the rules of how a 'productive' or 'good' day looks. Let go of guilt, ask for accommodations, and don't be afraid to take up space with your needs. Advocate for yourself. Also, get familiar with your pharmacy options, because the logistics of chronic illness can be half the battle.'
Zade: 'Do NOT give up! It does get better.'
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Yahoo

time18 minutes ago

  • Yahoo

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual (under the tongue) formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. 'The FDA approval of Tonmya as a first-line treatment for fibromyalgia represents a landmark advancement for the millions of people in the U.S. suffering from the debilitating pain this condition causes,' said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. 'At Tonix, we recognized the transformative potential of pursuing a new approach with Tonmya for fibromyalgia, a chronic overlapping pain condition (COPC), that has gone without innovation for many years. We are hopeful that effectively treating pain with Tonmya could help improve the lives of people with this chronic syndrome.' 'The chronic pain of fibromyalgia is debilitating to every aspect of a person's life, including causing sleep disturbance and fatigue, all of which can negatively impact someone's ability to carry out their daily activities,' said Sharon Waldrop, a person with lived experience and founder of the Fibromyalgia Association. 'For over 15 years, this community has been underserved and waiting for new treatment options. This approval is a promising step forward and brings renewed hope to millions.' The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. The most common adverse events (incidence ≥2% and at a higher incidence in Tonmya-treated patients compared to placebo-treated patients) included oral hypoesthesia (numbness in the mouth), oral discomfort, abnormal product taste, somnolence (drowsiness), oral paresthesia (tingling, pricking or burning in the mouth), oral pain, fatigue, dry mouth, and aphthous ulcer (canker sore). 'For many years, rheumatologists like myself and other healthcare professionals have had to manage fibromyalgia with limited options that do not adequately meet treatment needs for the majority of patients,' said Philip Mease, M.D., Director of Rheumatology Research at the Providence Swedish Medical Center and Clinical Professor at the University of Washington School of Medicine. 'Tonmya is a novel treatment approach that targets nonrestorative sleep that is characteristic of fibromyalgia and can impact core symptoms, specifically pain.' The latest Phase 3 trial, RESILIENT, was recently published in Pain Medicine with data on primary and secondary endpoints measuring pain, patient's global impression of change, patient-reported symptoms and function, sleep disturbance, and fatigue. 'I know firsthand how the chronic pain of fibromyalgia significantly disrupts my patients' lives.' Andrea L. Chadwick, M.D., MSc, FASA, Anesthesiology, Pain, and Perioperative Medicine at The University of Kansas Health System. 'Treatments that are processed through the liver can result in metabolites that could affect a medicine's efficacy and safety over time. Tonmya is administered sublingually which is designed to reduce pain quickly and durably with a tolerable safety profile.' Tonix thanks the participants and investigators involved in its fibromyalgia clinical trials, and FDA for its commitment to approving new treatments for this condition. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. For more information, visit or download the TONMYA Fact Sheet here. Webcast InformationTonix will host a webcast and conference call on Monday, August 18 at 8:30 AM ET to discuss the approval of Tonmya. The live webcast of the call will be available on the Investors section of Tonix's website: To participate by phone, please register in advance using this link to obtain a local or toll-free phone number and your personal pin. A replay of the webcast will be available for approximately 90 days following the live event. The slides presented during the webcast will be made available on the 'Presentations' page of the 'Investors' section of the Company's website. About FibromyalgiaFibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., approximately 80% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep (waking up tired and unrefreshed), fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Patients with fibromyalgia have double the medical costs compared to the general population in the U.S. About Tonmya™ (cyclobenzaprine HCl sublingual tablets)Tonmya, which was investigated as TNX-102 SL, is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride, which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a tertiary amine tricyclic (TAT) and multifunctional agent with potent binding and antagonist activities at the 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors, Tonmya is now approved as a once-daily bedtime treatment for fibromyalgia in adults. The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10357465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix's proprietary composition. These patents are expected to provide Tonmya with U.S. market exclusivity until 2034. Pending patent applications related to method of use could extend exclusivity until 2044. About the Phase 3 Clinical Trials: RELIEF and RESILIENTThe RELIEF and RESILIENT studies were double-blind, randomized, placebo-controlled trials designed to evaluate the efficacy and safety of Tonmya™ (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia. RELIEF and RESILIENT were two-arm trials that enrolled 503 and 457 adults with fibromyalgia across 40 and 33 United States sites, respectively. In both trials, the first two weeks of treatment consisted of a run-in period in which participants started on Tonmya 2.8 mg (1 tablet) or placebo. Thereafter, all participants increased their dose to Tonmya 5.6 mg (2 x 2.8 mg tablets) or two placebo tablets for the remaining 12 weeks. The primary endpoint across both trials was the daily diary pain intensity score change (Tonmya 5.6 mg vs. placebo) from baseline to Week 14 (using the weekly averages of the daily numerical rating scale scores). Additional details on RELIEF (NCT04172831) and RESILIENT (NCT05273749) are available on RALLY was a replicate Phase 3 trial to RELIEF and RESILIENT that demonstrated greater but non-significant treatment effect with Tonmya compared to placebo and demonstrated consistent safety. Results of this trial may not have been generalizable due to the presence of factors outside the conduct of the study. Additional details are available on (NCT04508621). Tonix Pharmaceuticals Holding is a fully-integrated biotechnology company. Tonix's development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology and infectious diseases. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, Inc., our wholly-owned commercial subsidiary, markets treatments for fibromyalgia and acute migraine. This press release and further information about Tonix can be found at Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the 'SEC') on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contacts Jessica Morris Tonix Pharmaceuticals (862) 799-8599 Brian Korb astr partners (917) 653-5122 Media Contact Meagen HagansWeber Shandwick(757)358-2033MHagans@ INDICATIONTONMYA is indicated for the treatment of fibromyalgia in adults. CONTRAINDICATIONSTONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs. During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. In patients with hyperthyroidism. WARNINGS AND PRECAUTIONS Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy. Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases. Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures. Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs. CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur. ADVERSE REACTIONSThe most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer. DRUG INTERACTIONS MAO inhibitors: Life-threatening interactions may occur. Other serotonergic drugs: Serotonin syndrome has been reported. CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced. Tramadol: Seizure risk may be enhanced. Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED). Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition. Pediatric use: The safety and effectiveness of TONMYA have not been established. Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions. Please see additional safety information in the full Prescribing Information. To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa
InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa

Yahoo

time18 minutes ago

  • Yahoo

InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa

Two of the region's leading organizations team up to elevate community-based care options for seniors across Tampa Bay. TAMPA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. ('InnovAge') (Nasdaq: INNV), a leader in senior care through the Program of All-inclusive Care for the Elderly ('PACE'), is proud to announce a new joint venture of its Tampa, Florida center, located at 4520 Seedling Circle, Tampa, Florida 33614 with Tampa General Hospital (TGH). This joint venture unites two mission-driven organizations dedicated to helping older adults in Hillsborough, Pasco and Hernando counties to live healthier, more independent lives. InnovAge expects the joint venture with Tampa General to elevate a shared commitment to expanding innovative community-based care options and improve access to quality care, particularly for the clinically frail and underserved seniors in the market. A Shared Commitment to Tampa Seniors Tampa General Hospital is the #1 hospital in the Tampa Bay region for the 10th consecutive year, according to U.S. News & World Report's 2025–2026 Best Hospitals rankings. Recognized nationally as among the top 10% of U.S. hospitals in Geriatrics, Tampa General is the region's only academic health system and a trusted source of high-quality, complex care for the senior population. Tampa General's commitment to maintaining optimal health for seniors and providing world-class care tailored to their unique needs is also recognized by the Institute for Healthcare Improvement (IHI) as an Age-Friendly Health System, at the highest level of designation—'Committed to Care Excellence.' PACE (Program of All-Inclusive Care for the Elderly) is a proven care model designed to help seniors live independently at home while receiving the health care and support they need. PACE delivers fully coordinated medical, dental, therapy, and social services—along with transportation and in-home support. An interdisciplinary care team works closely with each participant to create a personalized plan that promotes health, dignity and quality of life, often at no cost for those with dual Medicare and Medicaid coverage. 'We are thrilled to partner with Tampa General Hospital, an organization that shares our deep commitment to improving the health and quality of life of the communities we serve,' said Patrick Blair, InnovAge CEO. 'Together, we will bring the proven benefits of PACE to more seniors in the Tampa Bay area, helping them live safely and independently at home while receiving the comprehensive care they need. Tampa General's reputation for clinical excellence and community leadership makes them an ideal partner for InnovAge, and we are excited about the positive impact we can create together.' 'Innovation is in our DNA and we look for partners who share that same philosophy,' said John Couris, Tampa General Hospital President and CEO. 'InnovAge shares our vision of a healthier community for everyone, including our most vulnerable seniors. This joint venture reflects our mutual dedication to expanding access, creating innovative solutions and making a lasting difference in the lives of older adults in Tampa Bay.' The InnovAge Florida PACE center in Tampa has one of the largest footprints in the nation, with a 35,000-square-foot facility that can serve approximately 1,300 seniors. It offers primary and specialty medical care, dental services, rehabilitation therapies, transportation, meals, and engaging social activities—coordinated by a dedicated care team to help participants remain independent and connected to their community. Investor ContactRyan Kubotarkubota@ Media ContactLara HazenfieldInnovAge Public Relations & Content Creation Managerlhazenfield@ About InnovAgeInnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge's patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — 'win.' As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states. About Tampa GeneralTampa General Hospital, a 1,529-bed, not-for-profit academic health system, is one of the largest hospitals in America and delivers world-class care as the Tampa Bay region's only center for Level l trauma and comprehensive burn care. The system's hospitals include Tampa General Hospital, Tampa General Rehabilitation Hospital, Tampa General Behavioral Health Hospital which are all located in Tampa. Additionally, Tampa General Brooksville, Tampa General Spring Hill and Tampa General Crystal River anchor TGH's footprint in Hernando and Citrus counties. Tampa General Hospital is the highest-ranked hospital in Tampa Bay in U.S. News & World Report's 2025-2026 Best Hospitals, with six medical specialties ranking among the top 50 in the nation and five additional medical specialties ranked among the top 10% best hospital programs in the United States. As the first hospital in Florida to open a clinical command center for real-time situational awareness, Tampa General elevated its digital care coordination center to the next level by leveraging artificial intelligence (AI) and its analytics platform across both inpatient and outpatient care, ensuring patients receive leading-edge care as quickly and safely as possible. The academic health system's commitment to growing and developing its team members is recognized by three prestigious Forbes magazine rankings — in the 2025 America's Best Large Employers, the top 50 in Florida in the 2024 America's Best Employers by State and the 2023 America's Best Employers for Women. Tampa General is the safety-net hospital for the region, caring for anyone regardless of ability to pay; in fiscal year 2023, Tampa General provided a net community benefit of approximately $301.8 million in the form of health care for underinsured patients, community education and financial support to community health organizations in Tampa Bay. It was the nation's No. 1 adult solid organ transplant center in 2024 and is the primary teaching hospital for the USF Health Morsani College of Medicine. With five medical helicopters, Tampa General transports critically injured or ill patients from 23 surrounding counties to receive the advanced care their conditions require. Tampa General is home to a nationally accredited comprehensive stroke center and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It is home to the Muma Children's Hospital at TGH, the Jennifer Leigh Muma 82-bed neonatal intensive care unit and a nationally accredited rehabilitation center. Tampa General's footprint includes TGH North, which consists of three hospitals and several outpatient locations in Citrus and Hernando counties; 17 Tampa General Medical Group Primary Care offices; TGH Family Care Center Kennedy; two TGH outpatient centers; TGH Virtual Health; and 19 TGH Imaging outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents receive world-class care from the TGH Urgent Care, powered by the Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital ( For more information, go to This press release was published by a CLEAR® Verified individual.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store